Helius Medical Technologies, Inc. Announces Inducement Grants and Reports Negative Return on Investment
NEWTON, Pa. Aug. 16, 2024 - Helius Medical Technologies, Inc. (Nasdaq: HSDT), a leading neurotech company focused on neurological wellness, announced today that it has approved equity awards under Helius 2021 Inducement Plan as a material inducement to three new hires. The approval was made by the company’s independent directors in accordance with Nasdaq Listing Rule 5635(c)(4), which requires a public announcement of equity awards not made under a stockholder-approved equity plan.
The new equity awards, effective August 14, 2024, demonstrate Helius’ commitment to attracting and retaining top talent. By granting these awards, Helius aims to incentivize the individuals to join the company and contribute to its continued growth and success in the neurotech industry.
As per the press release, Helius Medical Technologies has recorded a cumulative net loss of $9 million during the 12 months ending in the first quarter of 2024. This has resulted in a negative return on investment (ROI) of -133.2%, indicating a decline in overall profitability. The negative ROI falls significantly below the average performance of other healthcare sector companies, with 515 reporting higher ROIs within the same period.
Furthermore, Helius Medical Technologies’ share price experienced a decline of -20.98% during the third quarter of 2024. This drop in share price further contributes to the challenges faced by the company and may reflect investor concerns about its financial performance.
These recent developments reflect a deterioration in Helius Medical Technologies’ overall ranking in terms of ROI. The company’s total ranking fell from 3,163 in the fourth quarter of 2023 to 3,258 in the most recent rankings, indicating a decline in its ability to generate returns on investments.
Despite these setbacks, Helius Medical Technologies remains optimistic about its future prospects. The company continues to focus on advancing its neurotech solutions and aims to regain stability and profitability in the coming quarters.
Comments